Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myeloma.

Trial Profile

Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myeloma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Antithymocyte globulin; Ciclosporin; Fludarabine
  • Indications Graft-versus-host disease; Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms LenaRIC
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 30 Jun 2015 to 19 Dec 2017.
    • 11 Jul 2017 Status changed from completed to active, no longer recruiting.
    • 06 Dec 2016 Results (n=40) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top